Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Consumer DNA firms get serious about drug development

Nature volume 520, pages 597–598 (2015) Cite this article

Subjects

Companies race to gather large data sets in bid to find treatments based on genetics.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Erika Check Hayden
    View author publications

    Search author on:PubMed Google Scholar

Related links

Related links

Related links in Nature Research

US regulators try to tame 'wild west' of DNA testing 2015-Feb-20

Giant gene banks take on disease 2014-Oct-14

Genome hacker uncovers largest-ever family tree 2013-Oct-28

Huge cancer study uncovers 74 genetic risk factors 2013-Mar-27

Related external links

Genes for Good

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Check Hayden, E. Consumer DNA firms get serious about drug development. Nature 520, 597–598 (2015). https://doi.org/10.1038/520597a

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/520597a

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research